cgd: Chronic Granulomatous Disease data

Description

Dataset from Fleming and Harrington (1991).

Data from a multicenter placebo-controlled randomized trial of gamma inferon in patients with chronic granulomatous disease (CGD). 128 patients were randomized to either gamma inferon ($n=63$) or placebo ($n=65$). For each patient the times from study entry to initial and any recurrent serious infections are available. There is a minimum of one and a maximum of eight (recurrent) infection times per patient, with a total of 203 records.

Usage

data(cgd)

Arguments

Format

a~data frame with 203 rows and 17 columns. There are the following variables contained in the data frame.

hospit: code of the hospital
ID: case identification number
RDT: date randomization onto study (mmddyy)
IDT: date of onset of serious infection, or date the patient was taken off the study (mmddyy)
trtmt: treatment code, 1 = rIFN-gamma, 2 = placebo
inherit: pattern of inheritance, 1 = X-linked, 2 = autosomal recessive
age: age in years
height: height of the patient in cm
weight: weight of the patient in kg
cortico: using corticosteroids at time of study entry, 1 = yes, 2 = no
prophy: using prophylatic antibiotics at time of study entry, 1 = yes, 2 = no
gender: 1 = male, 2 = female
hcat: hospital category, 1 = US-NIH, 2 = US-other, 2 = Europe - Amsterdam, 4 = Europe - other
T1: elapsed time (in days) from randomization (from sequence = 1 record) to diagnosis of a serious infection or, if a censored observation, elapsed time from randomization to censoring date; computed as IDT - RDT (from sequence = 1 record)
T2: 0, for sequence = 1 record, if sequence > 1, T2 = T1(from previous record) + 1
event: censoring indicator, 1 = non-censored observation, 2 = censored observation
sequence: sequence number, for each patient, the infection recods are in sequence number order

Source

Appendix D.2 of Fleming and Harrington (1991).

References

Fleming, T. R. and Harrington, D. P. (1991). Counting Processes and Survival Analysis. New York: John Wiley and Sons.